These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

48 related items for PubMed ID: 5584957

  • 1. The effect of hirudin, a potent antithrombin, on the thromboplastin generation test.
    Caldwell MJ.
    Thromb Diath Haemorrh; 1967 Feb 28; 17(1-2):256-63. PubMed ID: 5584957
    [No Abstract] [Full Text] [Related]

  • 2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP, Bernat A, Gaich C, Herbert M.
    Thromb Haemost; 2002 Feb 28; 87(2):238-44. PubMed ID: 11858483
    [Abstract] [Full Text] [Related]

  • 3. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL, Hansson GF, Sarich TC, Wolzt M.
    Thromb Res; 2004 Feb 28; 113(1):85-91. PubMed ID: 15081569
    [Abstract] [Full Text] [Related]

  • 4. [Hemostasis insufficiency in thrombin blockade by Hirudin].
    WITTE S, SCHRICKER KT.
    Thromb Diath Haemorrh; 1962 Jul 15; 7():491-8. PubMed ID: 14007758
    [No Abstract] [Full Text] [Related]

  • 5. Effects of hirudin (thrombin specific inhibitor) in zebrafish embryos: a developmental role for thrombin.
    Jagadeeswaran P, Liu YC, Eddy CA.
    Blood Cells Mol Dis; 1997 Dec 15; 23(3):410-4. PubMed ID: 9446755
    [Abstract] [Full Text] [Related]

  • 6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 15; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 7. CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3.
    Komatsu Y, Misawa S, Sukesada A, Ohba Y, Hayashi H.
    Biochem Biophys Res Commun; 1993 Oct 29; 196(2):773-9. PubMed ID: 8240353
    [Abstract] [Full Text] [Related]

  • 8. The action of factor Xa, thrombin and trypsin on human factor II.
    Kisiel W, Hanahan DJ.
    Biochim Biophys Acta; 1973 Dec 05; 329(2):221-32. PubMed ID: 4797461
    [No Abstract] [Full Text] [Related]

  • 9. [The use of the specific thrombin inhibitor hirudin in diagnostic and biochemical studies].
    Walsmann P.
    Pharmazie; 1988 Nov 05; 43(11):737-44. PubMed ID: 3073391
    [No Abstract] [Full Text] [Related]

  • 10. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
    Bexborn F, Engberg AE, Sandholm K, Mollnes TE, Hong J, Nilsson Ekdahl K.
    J Biomed Mater Res A; 2009 Jun 15; 89(4):951-9. PubMed ID: 18470919
    [Abstract] [Full Text] [Related]

  • 11. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW.
    Thromb Haemost; 1994 Sep 15; 72(3):377-80. PubMed ID: 7855787
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
    Arocas V, Lemaire C, Bouton MC, Bezeaud A, Bon C, Guillin MC, Jandrot-Perrus M.
    Thromb Haemost; 1998 Jun 15; 79(6):1157-61. PubMed ID: 9657441
    [Abstract] [Full Text] [Related]

  • 13. [Simultaneous determination of zymogen activation time and zymogen level using chromogenic substrates in blood coagulation analysis].
    Svendsen L, Brogli M, Stocker K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982 Jun 15; 109(1):150-6. PubMed ID: 6177596
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
    de Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A.
    Thromb Haemost; 2002 Aug 15; 88(2):253-8. PubMed ID: 12195697
    [Abstract] [Full Text] [Related]

  • 15. The inhibition of the intrinsic generation of activated factor X by heparin and hirudin.
    Brown JE, Baugh RF, Hougie C.
    Thromb Res; 2002 Aug 15; 17(1-2):267-72. PubMed ID: 7376133
    [No Abstract] [Full Text] [Related]

  • 16. [Microdetermination of an anti-thrombic activity: hirudin].
    JUTISZ M, MARTINOLI G, TERTRIN C.
    Bull Soc Chim Biol (Paris); 1962 Aug 15; 44():461-9. PubMed ID: 14452906
    [No Abstract] [Full Text] [Related]

  • 17. [Comparative properties of hirudin from whole leeches and from leech heads and bodies].
    Baskova IP, Cherkesova DU.
    Biokhimiia; 1980 Feb 15; 45(2):267-72. PubMed ID: 7388067
    [Abstract] [Full Text] [Related]

  • 18. [Biochemical and pharmacological aspects of the thrombin inhibitor hirudin].
    Walsmann P, Markwardt F.
    Pharmazie; 1981 Oct 15; 36(10):653-60. PubMed ID: 7031705
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids.
    De Filippis V, Quarzago D, Vindigni A, Di Cera E, Fontana A.
    Biochemistry; 1998 Sep 29; 37(39):13507-15. PubMed ID: 9753436
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass.
    Jormalainen M, Vento AE, Lukkarinen H, Kääpä P, Kytö V, Lauronen J, Paavonen T, Suojaranta-Ylinen R, Petäjä J.
    J Cardiothorac Vasc Anesth; 2007 Apr 29; 21(2):224-31. PubMed ID: 17418736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.